Abstract 200P
Background
Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the Survival of hepatocellular carcinoma (HCC) patients receiving TACE remains challenging.
Methods
This retrospective study included 1805 HCC patients receiving TACE. Each patient was randomized to a training set (n = 1264) and a validation set (n = 541). We investigated prognostic factors in the training set and developed an easily applicable ALFP (ALBI grade, AFP, and Prothrombin time) score, which was evaluated in the validation set.
Results
We built the ALFP score using baseline ALBI grade 2 or 3 (HR 1.301, 95% CI 1.073-1.577,p = 0.007) and AFP ≥ 100 ng/ml (HR 1.328, 95% CI 1.133-1.557, p < 0.001)and PT 13.1 s (HR 1.262, 95% CI 1.047-1.521, p=0.015), which were identified as unfavorable prognosis factors in a multivariate analysis. The median OS in patients with ALFP scores of 0, 1, 2, and 3 points was 50.1 months (95% CI NA), 33.6months (95% CI 27.4–39.8), and 20.4months (95% CI 18.0–22.8), and 12.7 months (95% CI 10.2–15.2), respectively; the difference was statistically significant (p < 0.001).the result were confirmed in the validation set(The median OS ,0/1/2/3 points = 42.5/32.6/20.4 /13.0 months, p < 0.0019).
Conclusions
The ALFP score can predict the prognosis of HCC patients receiving TACE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiong Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract